Canada · curated MDI catalog

Molecular diagnostic cancer tests available in Canada

This page shows tests for which MDI has a documented Canada market-access record. Commercial availability does not establish personal eligibility, reimbursement, appropriate use or authorization of the displayed test version.

7 curated profiles currently match this page. MDI lists them alphabetically and does not rank tests by isolated performance numbers, evidence counts, price or popularity.

• FoundationOne CDx — Tissue-based comprehensive genomic profiling and indication-specific companion diagnostic for solid tumors.
• FoundationOne Heme — DNA/RNA comprehensive genomic profiling LDT for hematologic neoplasms and other source-defined indications.
• FoundationOne Liquid CDx — Blood-based 324-gene comprehensive genomic profiling and companion-diagnostic test for advanced solid tumors. Regulatory claims are PMA-, supplement-, biomarker-, therapy- and indication-scoped.
• MammaPrint — 70-gene breast-cancer genomic risk classifier with multiple historical/current platform configurations that must remain version scoped.
• Oncotype DX Breast Recurrence Score — 21-gene tumor RNA expression assay used in HR-positive, HER2-negative early breast cancer to estimate recurrence risk and inform potential chemotherapy benefit.
• therascreen KRAS RGQ PCR Kit — FDA-approved real-time PCR KRAS companion diagnostic for colorectal cancer.
• therascreen PIK3CA RGQ PCR Kit — FDA-approved real-time PCR PIK3CA companion diagnostic for breast cancer.

How to interpret these records

Clinical purpose comes first. Historical evidence remains attached to the assay version that was actually studied. Evidence counts describe curation coverage, not test quality. Commercial availability is separate from authorization, reimbursement, eligibility and appropriate use.

Find all tests · Understand the evidence · Methodology & provenance